-
2024-516924-32-00
5
2025-10-17
Neovascular Age-Related Macular Degeneration (nAMD)
-
2025-520564-17-00
5
2025-10-16
Hidradenitis suppurativa (HS)
-
2025-521188-11-00
5
2025-10-15
Type 2 diabetes
-
2024-517632-22-00
5
2025-10-06
Hidradenitis Suppurativa
-
2025-521377-14-00
4
2025-10-06
Atrial fibrillation
-
2024-518325-15-00
5
2025-09-08
Gastroenteropancreatic neuroendocrine tumor (GEP-NET)
-
2025-520519-14-00
5
2025-09-03
Atherosclerotic Cardiovascular Disease
-
2023-508875-35-00
5
2025-09-01
Heart condition
-
2024-517247-31-00
5
2025-07-07
Newly Diagnosed Higher Risk Myelodysplastic Syndrome
-
2024-519219-32-00
5
2025-06-23
Heart Failure With Reduced Ejection Fraction
-
2024-515764-31-00
10
2025-06-13
Non-small cell lung cancer
-
2024-517458-90-00
5
2025-06-06
Chronic obstructive pulmonary disease (COPD)
-
2024-513959-33-00
4
2025-05-13
Asthma
-
2022-500747-21-00
4
2025-02-27
Geographic Atrophy
-
2023-509146-35-00
6
2025-01-30
Systemic Lupus Erythematosus
-
2024-519286-21-00
5
2024-12-17
MALIGNANT PLEURAL MESOTHELIOMA PATIENTS
-
2023-509717-36-00
5
2024-12-16
AF patients who have undergone successful PCI
-
2024-516839-27-00
4
2024-12-09
BRCA wild-type advanced ovarian, fallopian tube and primitive peritone
-
2024-518092-62-00
5
2024-12-09
Adult critically ill patients requiring non-invasive (NIMV) or invasiv
-
2024-517863-22-00
5
2024-12-01
Study population consists in patients with a diagnosis of mCRC who hav
-
2023-508475-36-00
5
2024-10-29
Atherosclerotic Cardiovascular Disease
-
2024-514304-14-00
1
2024-10-08
Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
-
2023-503895-25-00
5
2024-08-01
criticall illness
-
2023-508005-24-00
5
2024-08-01
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma